Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U. S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase.